

ANI PHARMACEUTICALS INC  
Form SC 13D/A  
November 25, 2013

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549**

**SCHEDULE 13D/A  
(Amendment No. 2)**

**Under the Securities Exchange Act of 1934**

**ANI Pharmaceuticals, Inc.**

(Name of Issuer)

**Common Stock, \$0.0001 par value per share**

(Title of Class of Securities)

**09065V203**

(CUSIP Number)

**Wayne C. Anderson**

**MVP Capital Partners**

**259 N. Radnor-Chester Road**

**Suite 130, Radnor, PA 19087**

**Tel: (610) 254-2999**

(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

**November 25, 2013**

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 09065V203 13D

1. Name of Reporting Persons  
Meridian Venture Partners II GP, L.P.  
("GP")
2. Check the Appropriate Box if a Member  
of a Group (See Instructions)  
(a)   
(b)  (1)
- SEC Use Only
4. Source of Funds (See Instructions)  
OO
5. Check if Disclosure of Legal  
Proceedings Is Required Pursuant to  
Items 2(d) or 2(e)
6. Citizenship or Place of Organization  
Delaware, United States of America
7. Sole Voting Power  
0 shares
- Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With
8. Shared Voting Power  
2,819,744 shares of Common Stock
9. Sole Dispositive Power  
0 shares
10. Shared Dispositive Power  
2,819,744 shares of Common Stock
11. Aggregate Amount Beneficially Owned  
by Each Reporting Person  
2,819,744 shares of Common Stock
12. Check if the Aggregate Amount in Row  
(11) Excludes Certain Shares (See  
Instructions)
13. Percent of Class Represented by  
Amount in Row 11  
29.7%(2)

14. Type of Reporting Person (See  
Instructions)  
PN

---

(1) This statement on Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2) Percentage is based on 9,480,206 shares of Company common stock, par value \$0.0001 per share, outstanding as of October 31, 2013.

2

13D

CUSIP No. 09065V203

1. Name of Reporting Persons  
Meridian Venture Partners II, L.P.  
("MVP II"),
2. Check the Appropriate Box if a Member  
of a Group (See Instructions)  
(a)   
(b)  (1)
3. SEC Use Only
4. Source of Funds (See Instructions)  
OO
5. Check if Disclosure of Legal  
Proceedings Is Required Pursuant to  
Items 2(d) or 2(e)
6. Citizenship or Place of Organization  
Delaware
7. Sole Voting Power  
0 Shares
8. Shared Voting Power  
2,819,744 shares of Common Stock
9. Sole Dispositive Power  
0 Shares
10. Shared Dispositive Power  
2,819,744 shares of Common Stock
11. Aggregate Amount Beneficially Owned  
by Each Reporting Person  
2,819,744 shares of Common Stock
- 12.

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With

Check if the Aggregate Amount in Row  
(11) Excludes Certain Shares (See  
Instructions)

13. Percent of Class Represented by  
Amount in Row 11  
29.7%(2)

14. Type of Reporting Person (See  
Instructions)  
PN

---

(1) This statement on Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D.

(2) Percentage is based on 9,480,206 shares of Company common stock, par value \$0.0001 per share, outstanding as of October 31, 2013.

CUSIP No. 09065V203 13D

1. Name of Reporting Persons  
Meridian Venture Partners II, Co. (“MVP Corp.”)
2. Check the Appropriate Box if a Member of a Group (See Instructions)  
(a)   
(b)  (1)
3. SEC Use Only
4. Source of Funds (See Instructions)  
OO
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6. Citizenship or Place of Organization  
Delaware
7. Sole Voting Power  
0 shares
- Number of Shares Beneficially Owned by Each Reporting Person With
8. Shared Voting Power  
2,819,744 shares of Common Stock
9. Sole Dispositive Power  
0 shares
10. Shared Dispositive Power  
2,819,744 shares of Common Stock
11. Aggregate Amount Beneficially Owned by Each Reporting Person  
2,819,744 shares of Common Stock
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
13. Percent of Class Represented by Amount in Row 11  
29.7%(2)

14. Type of Reporting Person (See  
Instructions)  
CO

---

(1) This statement on Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2) Percentage is based on 9,480,206 shares of Company common stock, par value \$0.0001 per share, outstanding as of October 31, 2013.

4



CUSIP No. 09065V203 13D

1. Name of Reporting Persons  
Robert E. Brown, Jr.
2. Check the Appropriate Box if a Member of a Group (See Instructions)  
(a)   
(b)  (1)
3. SEC Use Only
4. Source of Funds (See Instructions)  
OO
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6. Citizenship or Place of Organization  
United States of America
7. Sole Voting Power  
0 Shares
8. Shared Voting Power  
2,819,744 shares of Common Stock
9. Sole Dispositive Power  
0 Shares
10. Shared Dispositive Power  
2,819,744 shares of Common Stock
11. Aggregate Amount Beneficially Owned by Each Reporting Person  
2,819,744 shares of Common Stock
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
13. Percent of Class Represented by Amount in Row 11  
29.7%(2)

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With

14. Type of Reporting Person (See  
Instructions)  
IN

---

(1) This statement on Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2) Percentage is based on 9,480,206 shares of Company common stock, par value \$0.0001 per share, outstanding as of October 31, 2013.

5

CUSIP No. 09065V203 13D

1. Name of Reporting Persons  
Thomas A. Penn
2. Check the Appropriate Box if a Member of a Group (See Instructions)  
(a)   
(b)  (1)
3. SEC Use Only
4. Source of Funds (See Instructions)  
OO
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
6. Citizenship or Place of Organization  
United States of America
7. Sole Voting Power  
0 shares of Common Stock
- Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With
8. Shared Voting Power  
2,819,744 shares of Common Stock
9. Sole Dispositive Power  
0 shares of Common Stock
10. Shared Dispositive Power  
2,819,744 shares of Common Stock
11. Aggregate Amount Beneficially Owned by Each Reporting Person  
2,819,744 shares of Common Stock
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
13. Percent of Class Represented by Amount in Row 11  
29.7%(2)

14. Type of Reporting Person (See  
Instructions)  
IN

---

(1) This statement on Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2) Percentage is based on 9,480,206 shares of Company common stock, par value \$0.0001 per share, outstanding as of October 31, 2013.

6

**Introductory Note:** This Amendment No. 2 on Schedule 13D filed with the Securities and Exchange Commission (the "Commission") is being filed on behalf of Meridian Venture Partners II GP, L.P., a limited partnership organized under the laws of the State of Delaware ("GP"), Meridian Venture Partners II, L.P., a limited partnership organized under the laws of State of Delaware ("MVP II"), Meridian Venture Partners II, Co., a Delaware corporation ("MVP Corp.") and Messrs. Robert E. Brown, Jr. and Thomas A. Penn (collectively with GP, MVP II, and MVP Corp., the "Reporting Persons") in respect of shares of common stock, \$0.0001 par value per share ("Common Stock"), of ANI Pharmaceuticals, Inc.

**Item 1. Security and Issuer.**

This Amendment No. 2 on Schedule 13D (this "Schedule 13D") relates to the Common Stock of ANI Pharmaceuticals, Inc. and amends and further supplements the Schedule 13D filed by the Reporting Persons on July 1, 2013 (the "Initial Schedule 13D") as amended by the Reporting Persons by Amendment No. 1 to schedule 13D filed on November 14, 2013 (the Initial Schedule 13D as so amended, the "Statement"). The Reporting Persons are filing this Schedule 13D to report the cancellation by certain of the Reporting Persons of the agreement dated November 12, 2013 relating to proposed purchases of Common Stock. This cancellation was effective prior to the time any transactions were scheduled to occur under the trading plan. Except as expressly set forth herein, there have been no changes to the Statement. The Company's principal executive offices are located at 210 Main Street West, Baudette, Minnesota 56623.

**Item 4. Purpose of Transaction.**

As disclosed in the Initial Schedule 13D, the Reporting Persons may take future action (either alone or with one or more third parties) with respect to their investment in the Company's Common Stock as deemed appropriate in light of circumstances existing at such time, including the purchase of additional shares of Common Stock either in brokerage transactions in the open market or in privately negotiated transactions. On November 12, 2013, certain of the Reporting Persons executed an agreement in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, providing for the purchase by Meridian Venture Partners II, L.P. of up to 50,000 shares of Common Stock of the Company subject to predetermined criteria (the "Plan"). On November 25, 2013, such Reporting Persons terminated the Plan. No purchases were or made pursuant to such Plan.

**SIGNATURES**

After reasonable inquiry and to the best of the undersigned knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

November 25, 2013 Meridian Venture Partners II GP, L.P.

BY: Meridian Venture Partners II, Co.  
ITS: GENERAL PARTNER

By: /s/ Robert E. Brown, Jr.  
Robert E. Brown, Jr., President

November 25, 2013 Meridian Venture Partners II, L.P.

BY: Meridian Venture Partners II GP, L.P.  
ITS: GENERAL PARTNER

BY: Meridian Venture Partners II, Co.  
ITS: GENERAL PARTNER

By: /s/ Robert E. Brown, Jr.  
Robert E. Brown, Jr., President

November 25, 2013 Meridian Venture Partners II, Co.

By: /s/ Robert E. Brown, Jr.  
Robert E. Brown, Jr., President

November 25, 2013 ROBERT E. BROWN, JR.

By: /s/ Robert E. Brown, Jr.  
Robert E. Brown, Jr.

November 25, 2013 THOMAS A. PENN

By: /s/ Thomas A. Penn

Thomas A. Penn